#1
#1 out of 196.36%
business3h ago
Key facts: Merck prices $6B debt; CHMP backs Keytruda+Padcev for MIBC
- Merck priced a $6.0 billion debt deal with multiple notes due 2028 through 2056.
- The debt includes floating and fixed-rate notes with varied maturities.
- The EMA’s CHMP gave a positive opinion for Keytruda plus Padcev in perioperative MIBC.
- Regulatory decision on the Keytruda-Padcev combo is expected in Q3 2026 by the EC.
Vote 0